

## NIOX Group plc

### Board Changes

**Oxford, UK - 16 January 2025:** NIOX Group plc ("NIOX", the "Company" or the "Group"; AIM: NIOX), a medical device company focused on point of care asthma diagnosis, monitoring and management, is pleased to announce the following board changes.

Ian Johnson, currently Executive Chairman, will move to Non-Executive Chairman with effect from the 2025 AGM, which is expected to be held on 14 May 2025.

Jonathan Emms, currently Chief Operating Officer, has been appointed Chief Executive Officer with immediate effect.

Michael Roller, currently Chief Financial Officer, has indicated to the Board that he intends to retire with effect from the 2025 AGM, which is expected to be held on 14 May 2025. Michael will remain available to the Group as a consultant, as and when required.

Sarah Duncan, currently Group Financial Controller and Company Secretary, will succeed Michael as Chief Financial Officer on his retirement. Sarah has worked for the Group since 2018.

Sarah qualified as a Chartered Accountant with PwC and subsequently worked at Unipart for two years prior to joining the Group as Group Finance Manager in 2018 and becoming Company Secretary in November 2020. She was promoted to her current role in April 2024.

**Ian Johnson, NIOX's Executive Chairman, said:** *"The current executive team have worked together since the beginning of 2020 and have led the successful turnaround of the business. Jonathan's and Sarah's promotions from within the business are well deserved and provide stability and continuity. I congratulate both and wish them every success."*

#### Additional information

The following information is being disclosed pursuant to Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies in relation to the appointment of Sarah Elizabeth Duncan, aged 33, to the Board.

Sarah Duncan has been a director or partner of the following companies or partnerships during the five years preceding the date of this announcement:

Current directorships: Niox Healthcare Limited, Niox Limited, JMD Orthopaedics Limited

Past directorships (last five years): None

As at the date of this announcement, Sarah Duncan owns no shares in the Company and holds options over 506,219 shares in the Company.

Save as set out above there are no further disclosures required pursuant to Rule 17 or Schedule Two, paragraph (a) of

none as set out above there are no further disclosures required pursuant to Rule 11.01 of Schedule 11A, paragraph (5), of the AIM Rules for Companies.

## Contacts

### NIOX

Ian Johnson, Executive Chairman  
Jonathan Emms, Chief Executive Officer  
Michael Roller, Chief Financial Officer

Tel: +44 (0) 1865 405 560

Singer Capital Markets (Nominated Adviser and joint broker) Tel: +44 (0) 20 7496 3000  
Jen Boorer / James Fischer / James Todd

Investec Bank plc (joint broker)  
Ben Lawrence / Lydia Zychowska

Tel: +44 (0) 20 7597 5970

## About NIOX

Our mission is to improve asthma diagnosis, monitoring and management by greater patient access to FeNO testing.

Asthma is one of the biggest healthcare issues globally with 340 million sufferers, many of whom are undiagnosed or are misdiagnosed. The Group is engaged in the design, development, and commercialisation of medical devices for the measurement of FeNO, a precise biomarker for asthma. Our market leading device, NIOX VERO®, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical research organisations for respiratory studies.

NIOX provides products and services via its direct sales organisation and extensive distributor network in 50 countries. For more information, please visit [www.niox.com](http://www.niox.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAGPUACGUPAGMA